Do PT and APTT sensitivities to factors’ deficiencies calculated by the H47-A2 2008 CLSI guideline reflect the deficiencies found in plasmas from patients?
Do PT and APTT sensitivities to factors’ deficiencies calculated by the H47-A2 2008 CLSI guideline reflect the deficiencies found in plasmas from patients?

M. MARTINUZZO, L. BARRERA, M. RODRIGUEZ, M. A. D’ADAMO, M. S. LÓPEZ, J. C. OTASO

Grupo Bioquímico, Laboratorio Central, Hospital Italiano de Buenos Aires, CABA, Argentina

Correspondence:
Dr M Martinuzzo, Grupo Bioquímico, Laboratorio Central, Hospital Italiano de Buenos Aires, Peron 4190, Planta Baja. (C1181ACH), Ciudad Autónoma de Buenos Aires, Argentina. Tel.: (54) (11) 49990200 ext. 8857/ mobile (54) (11) (1555245312); Fax: (54) (11) 49990200 ext 8492;
E-mails: marta.martinuzzo@hospitalitaliano.org.ar and memartinuzzo@gmail.com

doi:10.1111/ijlh.12424

Received 29 March 2015; accepted for publication 20 July 2015

SUMMARY

Introduction: Prothrombin time (PT) and activated partial thromboplastin time (APTT) sensitivity for detecting isolated factor deficiencies varies with different reagents and coagulometers. The Clinical and Laboratory Standards Institute (CLSI) H47A2 guideline proposed a method to calculate these sensitivities, but some inconsistency has been reported. This study aimed to calculate factor sensitivities using CLSI guideline and to compare them with those obtained from single factor-deficient patients’ data.

Methods: Different mixtures of normal pooled and deficient plasmas were prepared (<1IU/dL to 100 IU/dL) according to the CLSI H47A2 guideline. PT with rabbit brain (RB) and human recombinant (HR) thromboplastins, APTT and factors’ activities were measured in an ACL TOP coagulometer. Sensitivities (maximum factor concentration that produces PT or APTT values out of the reference range) were calculated from mixtures and from patients with single-factor deficiencies: 17 factor FV, 36 FVII, 19 FX, 39 FVIII, 15FIX 15 FXI and 24 FXII.

Results: PT sensitivity with RB was as follows: FV 38 and 59, FVII 35 and 58, FX 56 and 64 IU/dL; PT sensitivity with HR was as follows: FV 39 and 45, FVII 51 and 50, FX 33 and 61 IU/dL; and APTT sensitivity was as follows: FV 39 and 45, FX 32 and 38, FVIII 47 and 60, FIX 35 and 44, FXI 33 and 43, FXII 37 and 46 IU/dL, respectively.

Conclusions: Reagent–coagulometer combination has adequate sensitivities to factor deficiencies according to guideline recommendations (>30 IU/dL). These should not be considered as actual sensitivities because those obtained by analysing patients’ plasmas with single-factor deficiencies were higher for most factors and could induce misinterpretation of the basic coagulation test results.
INTRODUCTION

Prothrombin time (PT) and activated partial thromboplastin time (APTT) are the most frequently used basic coagulation tests. PT is used for extrinsic pathway factor screening in patients with a bleeding history, liver disease and disseminated intravascular coagulation, and for the control of anticoagulation with oral antivitamin K antagonists. APTT is the test of choice to screen for deficiencies of intrinsic pathway factors VIII, IX, XI and XII. It is also used to monitor unfractioned heparin therapy, and it is one of the selected tests for lupus anticoagulant diagnosis [1].

Sensitivities of these tests to single-factor deficiencies could be important when explaining alterations in a routine presurgery evaluation, or for the detection of single-factor deficiencies in patients with bleeding manifestations or asymptomatic carriers of these defects, and are particularly important in haemophilia. Sensitivity varies according to tissue factor origin, phospholipid composition and concentration in thromboplastin reagent, as well as with the negatively charged activator, phospholipid source and concentration of APTT reagent. Additionally, the sensitivity of one particular reagent could be altered using different coagulation detection methods and instruments.

The sensitivity of reagent–instrument combinations can be determined by each laboratory using plasmas from deficient patients [2] or with mixtures of pooled normal and specific factor-deficient plasmas, as it was done for APTT in some studies some time ago [3], but plasmas from patients with single-factor deficiencies can be difficult to achieve due to the low prevalence of some deficiencies.

The Clinical and Laboratory Standards Institute (CLSI) H47A2 guideline [4] proposes that the sensitivity of APTT should be studied by performing the APTT on different mixtures of commercial normal pooled plasma and deficient plasmas. Normal control plasma and deficient plasmas were reconstituted with 1 mL of distilled water. Then, 10 different mixtures (1 mL final volume) were prepared at normal : deficient plasma ratios of 10 : 0, 9 : 1, 8 : 2, 7 : 3, 6 : 4, 5 : 5, 4 : 6, 3 : 7, 2 : 8, and 1 : 9.

MATERIALS AND METHODS

Samples

Data from consecutive patients tested to diagnose, confirm or follow isolated factor deficiencies (17 factor FV, 36 FVII, 19 FX, 24 haemophilia A, 15 von Willebrand diseases, 15 haemophilia B, 15 FXI and 24 FXII) between July 2012 and February 2015 were identified. All samples were negative for lupus anticoagulant or specific factor inhibitors. Results from 10 plasmas from healthy subjects were also included in the analyses.

The protocol was revised and approved by the Institutional Review Board (IRB) on human subject research of the Hospital Italiano de Buenos Aires Ethics Committee (CEPI). No written consent from patients was required because the study fulfilled the established criteria for handling discarded blood and patients’ data were collected retrospectively from the study records, identifiers were removed and the data used were anonymous.

Methods

Blood sampling: Blood was drawn by clean venipuncture into vacutainer tubes containing 1/10 volume of sodium citrated (Becton Dickinson, Franklin Lakes, NJ, USA). Platelet poor plasma was obtained by centrifugation at 200 g and room temperature for 10 min. The samples were handed according to the routine laboratory management protocol.

According to the CLSI H47A2 guideline [4], different mixtures of commercial normal pooled plasma (Normal Control Assayed, Instrumentation Laboratory (IL), Bedford, MA, USA) and deficient plasmas for each factor (IL) were prepared. Normal control plasma and deficient plasmas were reconstituted with 1 mL of distilled water. Then, 10 different mixtures (1 mL final volume) were prepared at normal : deficient plasma ratios of 10 : 0, 9 : 1, 8 : 2, 7 : 3, 6 : 4, 5 : 5, 4 : 6, 3 : 7, 2 : 8, and 1 : 9.
to achieve a range between <1 and 90–100 IU/dL of factor activity. PT was performed with two reagents from different origin: rabbit brain (RB) thromboplastin (PT Fibrinogen HS+, IL) and human recombinant (HR) thromboplastin (Recombiplastin 2G, IL). APTT with silica as activator was used (APTT SP, IL). Factor activities in the mixtures were measured using one-stage coagulation assays at three dilutions. HR thromboplastin for factors V, VII and X, and APTT SP for factors VIII, IX, XI and XII were used as reagents for factor activity measurement. All coagulation tests were performed in a photo-optical coagulometer (ACL TOP 700, Instrumentation Laboratory, Orangeburg, NY, USA).

PT, expressed as % of activity, was calibrated with HemosIL Calibration Plasma (IL) as standard with correction of the 100% activity time with the geometric mean normal prothrombin time. APTT was expressed in seconds (s). PT and APTT results of the mixtures were plotted against factor activities, and a nonlinear regression equation (one-phase association with a least-square fit selection) was applied.

Reference ranges had previously been established in our laboratory by analysing a large number (>5000) of results from previously defined healthy subjects according to the CLSI/IFCC C28-A3c guideline [7]. The reference range was 70–120% for the PT and 24–40 s for the APTT. Sensitivity was defined as the maximum factor concentration that produced a PT or APTT out of the reference range, <70% and >40 s, respectively.

**RESULTS**

We verified that the calculated sensitivities were only due to the effect of one deficient factor on the PT and APTT. Factor assays performed in commercial factor-deficient plasmas used for the sensitivity calculation demonstrated that activities were within the normal range for all factor components except the deficient one (Table 1). Table 1 also shows coagulation factor activities within the reference range of the commercial normal pooled plasma.

Factor activities in plasmas from patients were within the reference value for all except for the defi-

| Table 1. Levels of coagulation factors in commercial lyophilized pooled normal plasma and commercial deficient plasmas used to calculate sensitivities according to CLSI guideline |
|-----------------|----|----|----|----|----|----|----|----|
| Factor          | II | V  | VII| X  | VIII| IX | XI | XII|
| Normal Control Assayed | 96 | 91 | 90 | 94 | 101| 122| 78 | 83 |
| FII deficient   | <1 | 72 | 67 | <1 | 88 | 78 | 116| 80 | 88 |
| FV deficient    | 88 | <1 | 88 | 88 | 78 | 114| 83 | 69 |
| FVII deficient  | 85 | 95 | 1.1| 94 | 81 | 126| 105| 90 |
| FX deficient    | 86 | 99 | 90 | <1 | <1 | 68 | 106| 89 | 78 |
| FVIII deficient | 116| 64 | 127| 120| <1 | 95 | 70 | 87 |
| FIX deficient   | 111| 121| 107| 112| 111| <1 | 86 | 109|
| FXI deficient   | 116| 113| 115| 118| 107| 114| <1 | 109|
| FXII deficient  | 111| 104| 135| 110| 107| 114| 93 | <1 |

Results are expressed in factor activity (IU/dL) calculated using three dilutions of samples. Results in bold are those of the deficient factor on each commercial plasma used.
cient factor, confirming that patients included in the study presented a single-factor deficiency (Table 2).

Figures 1 and 2 show the nonlinear regression lines obtained from PT measured with RB and HR, respectively, against extrinsic pathway factor levels: FV (Figure 1a, 2a), FVII (Figure 1b, 2b) and FX (Figure 1c, 2c). Lines obtained by mixtures prepared according to CLSI guidelines and patients’ plasmas are shown. Factor activities present in patients’ plasmas were 20–140 IU/dL for FV, 10–148 IU/dL for FVII and 30–138 IU/dL for FX.

Curves obtained for APTT sensitivity to intrinsic pathway factor deficiencies are shown in Figure 3 (a–d). Factor activities present in patients’ plasmas used were between <1 and 168 IU/dL for FVIII, 2 and 150 IU/dL for FIX, <1 and 117 IU/dL for FXI and <1 and 102 IU/dL for FXII.

Table 3 summarizes all sensitivities calculated by the two approaches. The differences between nonlinear regression lines and between sensitivities were statistically significant for PT RB sensitivity to FV, FVII and FX, PT HR sensitivity to FVII only and APTT sensitivity to FV, FX and FVIII. All factor sensitivities calculated for patient plasmas were similar or higher than those calculated through the guideline procedure. PT and APTT sensitivities for FII deficiency were only calculated by guideline procedure (PT RB 33 IU/dL, PT HR 35 IU/dL and APTT 20 IU/dL) because no patients with a single deficiency of FII were included in this study.

**DISCUSSION**

The CLSI guidelines have established that, ideally, the sensitivity of APTT reagent–instrument combination has to be at least 30 IU/dL for factors VIII, IX and XI [4]. Moreover, PT and APTT within the reference values have been considered safe and used to guide transfusions in surgical interventions, assuming that factor activities were >30 IU/dL [8]. However, FVIII or FIX levels <60 IU/dL in haemophilic carriers have been found to increase (about two fold) the risk of bleeding manifestations, particularly after medical interventions [9]. Even FXI deficiency has variable bleeding tendency, and patients with levels of 40 IU/dL could present severe bleeding and low thrombin generation [10]. All these suggest that it is important to recognize mild deficiencies of these factors by the most used screening test, the APTT. Furthermore, it
has been reported that a particular APTT reagent–instrument combination did not detect a single-factor XI deficiency in a patient who bled more than expected during surgery [11]. The guidelines describe a procedure using commercially available pooled normal plasma and factor-deficient plasmas [4]. This guide procedure was considered as misleading because different sensitivities were calculated when different deficient plasmas were used, which was not explained by differences in concentrations of the other factors in them or by matrix effect of lyophilized materials compared to freeze–thaw specimens, because they also showed differences when thrombin generation tests were performed on deficient plasmas [6]. The authors of this article recommended against following the guideline in routine laboratories and suggested that the manufacturers’ data should be used or that the sensitivities should be calculated by processing...
samples of patients with single-factor deficiencies, instead. In our study, we followed the CLSI guideline procedure [4] and also calculated the sensitivities by analysing data obtained from the plasma of patients with a single-factor deficiency and demonstrated that our APTT reagent–instrument combination (micronized silica) had high sensitivity (>30 IU/dL) to all factors evaluated, except prothrombin, by following the CLSI guideline. The high APTT sensitivity obtained in our study is in concordance with that reported many years ago by Turi & Peerschke, who demonstrated that micronized silica reagents have good sensitivities to intrinsic pathway factor deficiencies [3]. However, we demonstrated that sensitivities calculated by analysing plasmas from patients with single-factor deficiencies were higher for all intrinsic pathway factors as well as for FV and FX, reaching statistically significance for FV, FX and FVIII. This is important because a mild APTT prolongation could be misinterpreted as a deficiency of factors VIII, IX or XI <35 IU/dL and provoke additional studies or delay before intervention when the real factor activity is around 50 IU/dL. Therefore, sensitivities calculated by the CLSI methods are artificial and could translate to inappropriate medical decisions.

We showed that the CLSI procedure could be followed to verify PT reagent–instrument sensitivity to single-factor deficiencies. It has been demonstrated that PT sensitivity to factors depends not only on the source of tissue factor, but also to phospholipid concentration and composition, as the presence of phosphatidylethanolamine increased sensitivity to FV deficiency and low concentration of phosphatidylserine decreased sensitivity to FII deficiency [12]. Moreover, it has been reported that traces of FVIIa present in tissue thromboplastins and NaCl concentration affected factor deficiency sensitivities and ISI [13]. Due to the variety of reagents and instruments in the market, knowledge of the sensitivity to mild factor deficiencies of the system used in the laboratory is important, in order to determine the levels needed to maintain patients free of bleeding. These levels have been estimated as 12 IU/dL for FV, 27 IU/dL for FVII, 56 IU/dL for FX and 43 IU/dL for combined FV+FVIII deficiency [14].

In PT, HR and RB thromboplastin sensitivities calculated by following CLSI guideline were also lower than those calculated by analysing data from patients.
with single-factor deficiencies. For both thromboplastins, sensitivities to all factors, except FII, were >30 IU/dL.

One weakness of our study is that patients’ plasmas were assayed at the time of blood collection for haemostasis evaluation and 3 different lots of APTT SP reagent were used during the study period. Nevertheless, the performance of each new lot of reagent was tested against the previous reagent with samples from single-factor-deficient, lupus anticoagulant and heparin plasmas to be sure that results were comparable. Acceptable and very consistent interlot results (CV <5%) were observed, and also many patients have been studied at various times, and the results were always the same (<5% of difference).

In conclusion, we demonstrated that single-factor deficiency sensitivity of PT and APTT calculated by H47A2 CLSI guideline procedure [4] should not be considered as actual sensitivities, because they are lower than those obtained from fresh plasmas of single-factor-deficient patients and could lead to erroneous interpretation of basic coagulation test results. However, as this study only demonstrated this difference for a particular manufacturer reagents/instrument system with high sensitivities, it would be interesting to verify these data for other reagent–instrument combinations.

**AUTHOR CONTRIBUTIONS**

Juan C Otaso and Marta Martinuzzo designed the research study; Luis Barrera contributed essential reagents and supplies, and collaborated with data analysis; Rodriguez Marcos, D’Adamo Maria A, López Marina S and Marta Martinuzzo performed the research; and Marta Martinuzzo analysed the data and wrote the study.

**REFERENCES**

2. Lawrie AS, Kitchen S, Purdy G, Mackie IJ, Preston FE, Machin SJ. Assessment of Actin

### Table 3. PT and APTT sensitivities calculated according to the CLSI H47A2 guideline or using plasmas from patients with a single-factor deficiency

<table>
<thead>
<tr>
<th>Test</th>
<th>Factor activity</th>
<th>II</th>
<th>V</th>
<th>P</th>
<th>VII</th>
<th>P</th>
<th>X</th>
<th>P</th>
<th>VIII</th>
<th>P</th>
<th>IX</th>
<th>P</th>
<th>XI</th>
<th>P</th>
<th>XII</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT (RB) CLSI</td>
<td>35</td>
<td>38</td>
<td>0.008</td>
<td>35</td>
<td>0.002</td>
<td>56</td>
<td>0.012</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients</td>
<td>–</td>
<td>59</td>
<td>58</td>
<td>64</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PT (HR) CLSI</td>
<td>33</td>
<td>39</td>
<td>0.169</td>
<td>51</td>
<td>0.004</td>
<td>33</td>
<td>0.049</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients</td>
<td>–</td>
<td>45</td>
<td>50</td>
<td>61</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APTT CLSI</td>
<td>19</td>
<td>39</td>
<td>0.0001</td>
<td>–</td>
<td>32</td>
<td>0.004</td>
<td>47</td>
<td>0.004</td>
<td>35</td>
<td>0.221</td>
<td>33</td>
<td>0.146</td>
<td>37</td>
<td>0.76</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients</td>
<td>–</td>
<td>45</td>
<td>–</td>
<td>38</td>
<td>–</td>
<td>60</td>
<td>44</td>
<td>43</td>
<td>46</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results of sensitivities are expressed as IU/dL of factor activity that produced PT and APTT results out of the reference range.

CLSI: Sensitivity calculated following the Clinical and Laboratory Standards Institute guideline procedure [4].

Patients: Sensitivity calculated using plasma from patients with a single-factor deficiency (expressed in italic).

P < 0.05 for extra-sum-of-F-test comparison between nonlinear regression lines obtained by both methods.

PT, prothrombin time; APTT, activated partial thromboplastin time; RB, rabbit brain; HR, human recombinant.
reagents to coagulation factor deficiencies.

4. Clinical and Laboratory Standards Institute (CLSI). One stage prothrombin time (PT) test and activated partial thromboplastin time (APTT) test. Approved guideline H47-A2. 28 (20), 2008. Clinical and Laboratory Standards Institute, Wayne, PA, USA.


